Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 31;15(12):e51395.
doi: 10.7759/cureus.51395. eCollection 2023 Dec.

Lipid Disorders and Cardiovascular Risk: A Comprehensive Analysis of Current Perspectives

Affiliations
Review

Lipid Disorders and Cardiovascular Risk: A Comprehensive Analysis of Current Perspectives

Maha Wazir et al. Cureus. .

Abstract

The increasing worldwide prevalence of cardiovascular diseases (CVDs) highlights the need to understand the complex relationships between lipid abnormalities and elevated cardiovascular risk. This review thoroughly investigates the complex terrain of lipid abnormalities, highlighting their crucial significance in developing CVDs. Dyslipidemia, which is closely connected to atherosclerosis, is a significant risk factor for CVDs, including coronary artery disease, myocardial infarction, and stroke. This review thoroughly examines the intricate relationship between lipoproteins, cholesterol metabolism, and the inflammatory cascade, providing a detailed comprehension of the mechanisms that contribute to atherogenic processes. An extensive analysis of the occurrence and distribution of lipid diseases worldwide indicates a concerning high frequency, which calls for a reassessment of public health approaches. Dyslipidemia is caused by a combination of genetic predispositions, lifestyle factors, and metabolic abnormalities, as supported by significant data. Moreover, investigating different types of lipoproteins and their specific functions in the development of atherosclerosis provides insight into the complex causes of CVDs. In addition to conventional lipid profiles, newly identified biomarkers and advanced imaging techniques are being carefully examined for their ability to improve risk classification and treatment strategies' effectiveness. From a critical perspective, the review thoroughly examines the current state of lipid-modifying medicines, specifically statins, fibrates, and new therapeutic approaches. The text discusses the emerging concept of precision medicine, which involves tailoring treatment approaches to individuals based on their genetic and molecular characteristics. This approach has the potential to improve treatment outcomes. In addition, this study critically assesses the effects of lifestyle changes and nutritional interventions on lipid homeostasis, offering a comprehensive view of preventive strategies. This review consolidates current viewpoints on lipid diseases and their complex correlation with cardiovascular risk. This review contributes to the ongoing cardiovascular disease prevention and management dialogue by clarifying the molecular mechanisms, exploring new therapeutic options, and considering broader societal implications.

Keywords: atherosclerosis; cardiovascular risk; dyslipidemia; lipid disorders; lipoprotein subtypes; precision medicine in cardiovascular health.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Two transcripts of HMG-CoA reductase related with developmental regulation from Scylla paramamosain: evidences from cDNA cloning and expression analysis. Zhao M, Jiang K, Song W, et al. IUBMB Life. 2015;67:954–965. - PubMed
    1. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian working Group Consensus Conference. Mancini GB, Baker S, Bergeron J, et al. Can J Cardiol. 2011;27:635–662. - PubMed
    1. Approach to patients with statin intolerance: evidence-based review (Article in Portuguese) Almeida JT, Esteves AL, Martins F, Palma I. Acta Med Port. 2020;33:49–57. - PubMed
    1. International lipid expert panel (ILEP): why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels. Bianconi V, Banach M, Pirro M. Trends Cardiovasc Med. 2021;31:205–215. - PubMed
    1. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Tachibana-Iimori R, Tabara Y, Kusuhara H, et al. Drug Metab Pharmacokinet. 2004;19:375–380. - PubMed

LinkOut - more resources